PRECISION BIOSCIENCES INC

Rule 10b5-1 Trading Plan

On September 29, 2025, Dario Scimeca, our General Counsel, entered into a trading plan intended to satisfy the affirmative defense conditions under Rule 10b5-1(c). Mr. Scimeca’s trading plan provides for the sale of, in the aggregate, up to 2,821 shares of our common stock from December 30, 2025 through November 10, 2026, unless the plan is earlier terminated. The 2,821 share aggregate limit represents the maximum number of shares that may be sold pursuant to Mr. Scimeca's Rule

10b5-1 plan. The actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the written plan.

Termination of Novartis Agreement

On October 31, 2025, we received written notice from Novartis Pharma AG (“Novartis”) of its termination of the Collaboration and License Agreement, dated June 14, 2022, between Novartis and us (the “Novartis Agreement”). The notice informed us that Novartis was exercising its right pursuant to Section 15.3.2 of the Novartis Agreement to terminate the Novartis Agreement in its entirety without cause upon 90 days’ prior written notice to us. The termination will be effective on January 30, 2026. Although Novartis and Precision have concluded work in the area of hemoglobinopathies, Precision and Novartis continue to explore a research collaboration in an area of joint therapeutic interest, which has not been disclosed.

We and Novartis entered into the Novartis Agreement to collaborate to discover and developin vivo gene editing products incorporating our custom ARCUS nucleases for the purpose of seeking to research and develop potential treatments for certain diseases, including certain hemoglobinopathies such as sickle cell disease and beta thalassemia. Pursuant to the Novartis Agreement, in exchange for upfront and potential milestone, option, and royalty payments, as well as certain research funding and a related equity investment by Novartis, we granted Novartis exclusive licenses and options to certain licensed products. As of the effective date of the termination, all options and licenses granted to Novartis will be terminated and will revert to us, including with respect to sickle cell disease and beta thalassemia, and we will no longer be required to satisfy any remaining performance obligations under the Novartis Agreement or entitled to receive any future milestone, royalty, option or other payments from Novartis.

As a result of the progress made to develop a nuclease for sickle cell disease, we intend to explore opportunities to develop the returned programs in partnership with others. Importantly, the return of these programs does not impact our near-term clinical priorities to finish the Phase 1 ELIMINATE-B trial for PBGENE-HBV and commence the Phase 1 trial for PBGENE-DMD, or our expected cash runway to achieve these clinical data milestones.